Viiv Healthcare

This study offers continued access to HIV medications (fostemsavir or dolutegravir/lamivudine) for 183 people who completed earlier ViiV Healthcare studies and are still benefiting. The goal is to provide treatment while collecting more safety information. Participants must have …

This study tests whether a new ultra-long-acting injectable HIV medication works as well as the current long-acting version. About 564 adults and teens with well-controlled HIV will receive either the ultra-long-acting or the standard long-acting shots. The goal is to see if the …

This study tests a new long-acting injectable drug called VH4524184 in healthy adults to see if it is safe and how the body handles it. The goal is to find a dose that could one day help control HIV with fewer shots. About 268 volunteers will receive either the drug or a placebo …

This study is testing a new experimental drug called VH4524184 for people with HIV-1 who have never taken HIV medication before. About 150 adults will receive either a low or high dose of VH4524184 along with two standard HIV drugs (emtricitabine and tenofovir alafenamide), or a …

This early-stage study tests a new experimental HIV drug called VH4770359 in 214 healthy adults aged 18-55. The goal is to check its safety, side effects, and how the body processes it. Participants will take either the drug or a placebo, and some will also receive midazolam to s…

This study looks at whether the HIV drug cabotegravir is safe for newborns who were exposed to HIV during birth. About 44 healthy babies will receive the drug either by mouth or injection. The goal is to find the right dose and check for side effects, helping to protect these inf…

This early-stage study is testing a long-acting injectable HIV prevention drug called cabotegravir, combined with an enzyme (rHuPH20) that helps the drug spread under the skin. The goal is to see if this combination is safe and how the body processes it in 214 healthy adults. Res…

This early-stage study tests a new long-acting injectable drug, VH4011499, in 168 healthy adults without HIV. The goal is to see if it is safe and how the body processes it, as a potential future option for HIV prevention. Participants receive one or more doses of the drug or a p…

This early-phase study will give 9 healthy adults a single dose of the experimental HIV drug VH4524184, plus a tiny radioactive version to track it. Researchers will measure how much of the drug gets into the blood, how it's broken down, and how it leaves the body through urine a…